Partner, Cambridge Innovation Capital (CIC)
Dr Michael Anstey specialises in life science investments and manages CIC’s investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.
Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early-stage life science businesses.
Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.